Versartis shares hammered by a PhIII flop as growth hormone flunks key test
Two years after Versartis $VSAR got out from under a clinical hold on somavaratan (VRS-317), the biotech says its big Phase III study proved to be a bad flop.
The long-acting form of recombinant human growth hormone failed to meet the primary endpoint for non-inferiority in a comparison against daily Genotropin, with the standard of care actually beating out the experimental rival. Height velocity for somavaratan twice monthly was 9.44 cm, versus 10.70 cm for those receiving Genotropin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
